A phase I, single ascending dose trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP 43742 in healthy volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 May 2016
At a glance
- Drugs VTP 43742 (Primary)
- Indications Autoimmune disorders; Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Vitae Pharmaceuticals
- 17 May 2016 Results of this and other study (see profile 255432) presented at the IMMUNOLOGY 2016™ American Association of Immunologists Annual Meeting
- 09 May 2016 Data will be presented at the IMMUNOLOGY 2016, the American Association of Immunologists' annual meeting according to a Vitae Pharmaceuticals media release.
- 08 Sep 2015 Top-line results were published in a Vitae Pharmaceuticals media release.